Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NELLR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzhb2pRUUN3ME2wMlAxPjZ7IN88US=> NGDiXpFUSU6JRWK=
MV-4-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS1NZhKSzVyPUCuNFE2QDZizszN M3fGV3NCVkeHUh?=
NKM-1 NHP1[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO3ZndYUUN3ME2wMlAyPjl7IN88US=> M13oZ3NCVkeHUh?=
ML-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Oy[GlEPTB;MD6wNVk5OyEQvF2= M{K3W3NCVkeHUh?=
BV-173 MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXTWYExUUN3ME2wMlAzOzF2IN88US=> NImzNGRUSU6JRWK=
RS4-11 MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH4TWM2OD1yLkCyOVg4KM7:TR?= M{izdnNCVkeHUh?=
HL-60 NF;CVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMEK5NFgh|ryP NFH2VGNUSU6JRWK=
KY821 M4DQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XUU2lEPTB;MD6wNlk4PSEQvF2= Mk\rV2FPT0WU
ECC10 NH7scVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMEO3PVIh|ryP MYXTRW5ITVJ?
NCI-H720 NXTjcFRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHES|BKSzVyPUCuNFQxOTFizszN Mn25V2FPT0WU
QIMR-WIL NW\WVoZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrKO2ZrUUN3ME2wMlA1Ojh5IN88US=> NGHzO4pUSU6JRWK=
KG-1 NGjjTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XodGlEPTB;MD6wOFQ5PiEQvF2= M2HGfnNCVkeHUh?=
TGW NGfWTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jDWmlEPTB;MD6wOFY{OyEQvF2= NH2wdnJUSU6JRWK=
ATN-1 NY\xR3dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;ZZWlEPTB;MD6wOFc{OyEQvF2= NU\TWXZFW0GQR1XS
RH-18 NWLQcJlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X2O2lEPTB;MD6wOlA1QCEQvF2= NFjHd2ZUSU6JRWK=
EW-18 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrKO45IUUN3ME2wMlA3QDRzIN88US=> MXvTRW5ITVJ?
NB17 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfiTWM2OD1yLkC3NVI1KM7:TR?= NYDFcmg3W0GQR1XS
SK-NEP-1 NHfhUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjWWmRKSzVyPUCuNFczOTNizszN MmXDV2FPT0WU
P12-ICHIKAWA M1THOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PJ[GlEPTB;MD6wO|c4QCEQvF2= NWi3cGVEW0GQR1XS
KARPAS-45 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMEe4NVUh|ryP NV3rbm5QW0GQR1XS
EW-3 M1\CPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjwWmNKSzVyPUCuNFgxPTNizszN NHP4NIRUSU6JRWK=
NB13 NYjsZWtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjPWW5KSzVyPUCuNFgzODNizszN NUDjXXRSW0GQR1XS
NCI-H209 M3PC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMEi3NFQh|ryP MXTTRW5ITVJ?
NCI-H1092 M2LsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMUCyO|Uh|ryP Mn22V2FPT0WU
NH-12 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHaN3pyUUN3ME2wMlExPzR2IN88US=> MX\TRW5ITVJ?
697 M3\GWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfXbJJrUUN3ME2wMlExQDN7IN88US=> MmK1V2FPT0WU
KE-37 NU\tUZpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[wZWlEPTB;MD6xNVM4KM7:TR?= Mn3XV2FPT0WU
MOLT-4 M{HINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlSwTWM2OD1yLkG1NVY6KM7:TR?= NVjsV|N5W0GQR1XS
CHP-134 NYDWdo9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGj0O4tKSzVyPUCuNVY{ODZizszN Mlu2V2FPT0WU
D-283MED NFKycmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULlZZZUUUN3ME2wMlE4Pjh4IN88US=> MlnZV2FPT0WU
LU-135 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnUblZTUUN3ME2wMlE5PTV{IN88US=> MVXTRW5ITVJ?
LU-134-A MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnBflVKSzVyPUCuNVg3PzFizszN NXjLbVI3W0GQR1XS
EM-2 M3\VPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXpZlNKSzVyPUCuNVk6OThizszN NUG5XGtzW0GQR1XS
LU-139 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMkC0PVgh|ryP MnLSV2FPT0WU
ALL-PO M2PLNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK2TWM2OD1yLkKxPVg5KM7:TR?= NF3uWGJUSU6JRWK=
NB12 Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrwTWM2OD1yLkKzNVE2KM7:TR?= NXnKWVFVW0GQR1XS
KP-N-YN MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jQZmlEPTB;MD6yN|U4OyEQvF2= NGjsPZFUSU6JRWK=
BEN M4PSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\vT|NWUUN3ME2wMlI{QTZ6IN88US=> MljZV2FPT0WU
HCC1569 NEiwSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jWcWlEPTB;MD6yOVExPiEQvF2= NUToNm5nW0GQR1XS
HuO9 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PSZWlEPTB;MD6yOlcyPSEQvF2= MmDDV2FPT0WU
WM-115 M3TDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLrTWM2OD1yLkK3O|M5KM7:TR?= MWPTRW5ITVJ?
CCRF-CEM M4jBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwM{O1Nlkh|ryP Mo[xV2FPT0WU
IST-SL1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwM{WzOFMh|ryP MVTTRW5ITVJ?
BE-13 NWLNUpdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn1UHA{UUN3ME2wMlM3PDV7IN88US=> MVfTRW5ITVJ?
COR-L88 NHTMPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XLdGlEPTB;MD6zOlU1KM7:TR?= NYPy[FRHW0GQR1XS
DOHH-2 MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNEGwNlMh|ryP M{DRO3NCVkeHUh?=
A704 NY\QWVZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwNEK2O{DPxE1? M{TQb3NCVkeHUh?=
KNS-81-FD M37IUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X0dWlEPTB;MD60OFAyPyEQvF2= NHfaeZBUSU6JRWK=
RPMI-8226 M3vBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrtcY1KSzVyPUCuOFU3PTJizszN NX7WcGptW0GQR1XS
TGBC24TKB M3TqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC3TWM2OD1yLkS1O|c5KM7:TR?= NIrtbpRUSU6JRWK=
NCI-H1304 M1fOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjpb2dKSzVyPUCuOFYyPTdizszN M3;LTnNCVkeHUh?=
MOLT-13 M4iw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXRTWM2OD1yLkS2OlE{KM7:TR?= NHLES5ZUSU6JRWK=
EW-22 MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwNE[2O|Eh|ryP MYfTRW5ITVJ?
MS-1 NEX0bpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwNE[5N|Mh|ryP NGiyXGhUSU6JRWK=
RMG-I NHjNOYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLyTWM2OD1yLkS5OFY1KM7:TR?= Mn36V2FPT0WU
NTERA-S-cl-D1 NGHORmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjKSJlDUUN3ME2wMlUxODF7IN88US=> NXO4XlVDW0GQR1XS
NCI-H1048 M{nXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwNUC5OVMh|ryP NI\KSW9USU6JRWK=
SW1417 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfETWM2OD1yLkW1OFM5KM7:TR?= NHu1c5dUSU6JRWK=
DB M4\Iemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHJ[2hKSzVyPUCuOVcxQCEQvF2= NXHMNohPW0GQR1XS
MEG-01 Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf2PYZmUUN3ME2wMlU5OzJizszN M{mwTXNCVkeHUh?=
EW-13 M3u0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O3bWlEPTB;MD61PFM1OSEQvF2= NWLlfnI5W0GQR1XS
LAMA-84 NHm3[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPBcYpLUUN3ME2wMlU6OjB5IN88US=> MkjlV2FPT0WU
J-RT3-T3-5 NEPqfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T3NmlEPTB;MD62NFgxQCEQvF2= MorVV2FPT0WU
MOLT-16 NGTjXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwNkWyOlQh|ryP MlXNV2FPT0WU
DU-4475 NH[zRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rmOGlEPTB;MD62OVQzPyEQvF2= MUnTRW5ITVJ?
HAL-01 NFK3XFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f1T2lEPTB;MD63NlU1QSEQvF2= MYfTRW5ITVJ?
RD MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDwTWM2OD1yLke1PFk6KM7:TR?= MULTRW5ITVJ?
OAW-28 MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwN{izO{DPxE1? NVnvUFh[W0GQR1XS
HCC38 NYL0NZVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPuXW1KSzVyPUCuPFAyQSEQvF2= NXzOWpBZW0GQR1XS
NMC-G1 M{\jWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHnTWM2OD1yLkixNVIyKM7:TR?= MWLTRW5ITVJ?
EW-16 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHMeWtJUUN3ME2wMlgyOzJ6IN88US=> M1O3cHNCVkeHUh?=
DU-145 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwOEm5NlMh|ryP M{j6cHNCVkeHUh?=
HPAF-II NWq1PIVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD5enE2UUN3ME2wMlkzPjJ6IN88US=> NVqyb5g5W0GQR1XS
A427 M4nUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP6NZN3UUN3ME2wMlk{ODJ{IN88US=> MUHTRW5ITVJ?
PA-1 M4Wwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqwTWM2OD1yLkm1OlQzKM7:TR?= NFr6NWJUSU6JRWK=
OAW-42 MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP2XplKSzVyPUCuPVYyPDZizszN NHfB[pdUSU6JRWK=
L-428 NFzER|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT3SZJKSzVyPUGuNFEzPSEQvF2= NIPwSGxUSU6JRWK=
COLO-824 MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LESWlEPTB;MT6wNVcxQCEQvF2= NWTNcG5sW0GQR1XS
P30-OHK M1THemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn5b2RFUUN3ME2xMlA1Pjh6IN88US=> Mlj2V2FPT0WU
NCI-H2170 NGfsfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFwME[yN{DPxE1? Ml7oV2FPT0WU
HCC2998 NGXmTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjrXmxuUUN3ME2xMlA4OTN3IN88US=> MoTKV2FPT0WU
NB14 NXWyc|dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7zTWM2OD1zLkGzO|Q5KM7:TR?= M3zjVnNCVkeHUh?=
TGBC1TKB NXnGUJNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjaPIxKSzVyPUGuNVQyPTJizszN MXnTRW5ITVJ?
KP-N-YS MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLsTWM2OD1zLkG2NlM3KM7:TR?= M3;rW3NCVkeHUh?=
CAL-120 NUPFdm1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDYTWM2OD1zLkG2OFI6KM7:TR?= NEHadnZUSU6JRWK=
SBC-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIexNWhKSzVyPUGuNVkxPTNizszN MWjTRW5ITVJ?
C32 NWjlXpBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrsTWM2OD1zLkG5NFg5KM7:TR?= MXLTRW5ITVJ?
HCC2157 Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvHTWM2OD1zLkG5OFk1KM7:TR?= MlTQV2FPT0WU
COLO-792 M{\TSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPPTWM2OD1zLkKwNFcyKM7:TR?= NHHPd5hUSU6JRWK=
ES7 NVmydZRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLGSJRKSzVyPUGuNlc6PTFizszN NEfZe5NUSU6JRWK=
HEL NHfJbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PKWmlEPTB;MT6zNVAzQSEQvF2= NFf4XpVUSU6JRWK=
ES4 M{GyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjD[21KSzVyPUGuN|Q6QThizszN MYrTRW5ITVJ?
NCI-SNU-1 NFO4bWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK1PZJoUUN3ME2xMlM3PTV3IN88US=> M4HOVHNCVkeHUh?=
MDA-MB-415 M1;sT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P3S2lEPTB;MT6zPFg2KM7:TR?= MkLUV2FPT0WU
NCI-H2342 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFwNECyOlkh|ryP NHHmSXlUSU6JRWK=
NB69 NX\HRY5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHGTWM2OD1zLkS2NlcyKM7:TR?= NFSyT4VUSU6JRWK=
D-247MG NIfYVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwNUGxNlIh|ryP MlOyV2FPT0WU
SCC-4 Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFwNUm4PFch|ryP MlSzV2FPT0WU
HuH-7 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjpTWM2OD1zLk[3Nlk{KM7:TR?= M{m3N3NCVkeHUh?=
A388 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK5TWM2OD1zLk[4O|I1KM7:TR?= Mle4V2FPT0WU
Calu-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rRVGlEPTB;MT63NFY6PyEQvF2= MkDrV2FPT0WU
NCI-H1648 Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zG[mlEPTB;MT63NVQyQCEQvF2= NF73clFUSU6JRWK=
NCI-H2052 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC2TIlKSzVyPUGuO|IzODFizszN NX6yU5B6W0GQR1XS
Ramos-2G6-4C10 Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFwN{O2OVYh|ryP NVTxc|UyW0GQR1XS
DEL MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPyPZpCUUN3ME2xMlc1Pjl{IN88US=> NEHsPXVUSU6JRWK=
SNU-423 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwN{ixOVch|ryP MlzIV2FPT0WU
COR-L23 NH\xNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXOSJdKSzVyPUGuO|k5PzRizszN M3zNVHNCVkeHUh?=
OMC-1 NW\SUXVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGj5Sm1KSzVyPUGuPFYxOTZizszN NFWyclRUSU6JRWK=
EW-11 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\DTWM2OD1zLkm1OlU4KM7:TR?= MnH0V2FPT0WU
HSC-3 MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvRT4ZKSzVyPUGuPVY{PjVizszN M4nxTXNCVkeHUh?=
MLMA M{PHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOxfXlKSzVyPUGuPVY3PzdizszN M3vrO3NCVkeHUh?=
RCM-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\sfXRkUUN3ME2yMlAxOzl7IN88US=> Mn3LV2FPT0WU
MFE-280 M3vtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETT[HRKSzVyPUKuNFI5PDhizszN NGXrdoFUSU6JRWK=
ES8 NFLobGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLDTWM2OD1{LkK1OFcyKM7:TR?= M{ft[3NCVkeHUh?=
TE-11 NIfBe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHJTWM2OD1{LkK5OFc{KM7:TR?= NYrLOWxuW0GQR1XS
HuO-3N1 NUX2ZnNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTFTWM2OD1{LkS4O|gh|ryP Mlm1V2FPT0WU
MHH-NB-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;UTWM2OD1{LkWxNVU5KM7:TR?= M{f5NnNCVkeHUh?=
TGBC11TKB MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETuVXJKSzVyPUKuOVc3QDFizszN MkH3V2FPT0WU
HOP-92 NUnmUHF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJwNUi3OFMh|ryP NVTkOFM6W0GQR1XS
IGR-1 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJwNkKwN|Uh|ryP NGixTWlUSU6JRWK=
GOTO MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTsOnk4UUN3ME2yMlY2Ozd5IN88US=> Mn;5V2FPT0WU
NCI-H1650 NX76W3c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HhXWlEPTB;Mj63NlIyPSEQvF2= MX3TRW5ITVJ?
NCI-H1581 NGnmenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:3TWM2OD1{Lke5OlgyKM7:TR?= MUHTRW5ITVJ?
NCI-H2405 MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSzdIM{UUN3ME2yMlgzPzh{IN88US=> NUfF[|hpW0GQR1XS
U-118-MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJwOU[0PVEh|ryP MkfSV2FPT0WU
DoTc2-4510 M1y1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTNwMEG0NVch|ryP MVLTRW5ITVJ?
NCI-H596 NIjscmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW3TVlKSzVyPUOuNFQ6QTdizszN NYC0TpZQW0GQR1XS
MPP-89 M1HBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nZZmlEPTB;Mz6wOVY3PiEQvF2= Mnr6V2FPT0WU
GCIY M2P1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTNwMkC0PVEh|ryP NVjyTYZmW0GQR1XS
SW626 NGW2W25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTNwMkS1OFMh|ryP NFzRVI9USU6JRWK=
OCI-AML2 NVyxbJA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zNOWlEPTB;Mz6zNVI4OiEQvF2= NXjzVJltW0GQR1XS
NBsusSR NUHmO496T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTNwM{S5N|gh|ryP NYLVeWNSW0GQR1XS
AN3-CA NE\N[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LOfWlEPTB;Mz60OFI{QCEQvF2= NF3ofVJUSU6JRWK=
EFM-19 NILZVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i5c2lEPTB;Mz60PFM{QSEQvF2= NG\3TYtUSU6JRWK=
RVH-421 NX;JdVVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljnTWM2OD1|LkW2PFc4KM7:TR?= Ml\KV2FPT0WU
5637 NWHNWWs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEGzepJKSzVyPUOuOlEyODNizszN Mn;wV2FPT0WU
PANC-08-13 NVj1Tm92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjrO3ZKSzVyPUOuOlM1PzJizszN M1fBTnNCVkeHUh?=
H9 NVL5Vm1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDtTWM2OD1|Lk[3NVQ1KM7:TR?= MVXTRW5ITVJ?
KARPAS-299 NFLGfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXpTWM2OD1|Lk[3N|YyKM7:TR?= NUjXWmdbW0GQR1XS
TE-5 NW\rZmVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfRNXFKSzVyPUOuO|A4ODlizszN NFXlSJJUSU6JRWK=
NOS-1 NXv5[GQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjiOG1GUUN3ME2zMlc6QDN2IN88US=> MUHTRW5ITVJ?
HH NWTsOWh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf1R3NKSzVyPUOuPFM5PjhizszN NFXZT4NUSU6JRWK=
769-P NEXFdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TtWmlEPTB;Mz64PVUyKM7:TR?= NVTzfY1SW0GQR1XS
CHP-212 MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTNwOUK1OFkh|ryP NUT5OFFMW0GQR1XS
NCI-H82 NIDrRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHvRZhKSzVyPUOuPVU6OzZizszN MWfTRW5ITVJ?
Mo-T MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXnTWM2OD12LkC0N|EzKM7:TR?= MWrTRW5ITVJ?
BB65-RCC NFyyeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXWbnpKSzVyPUSuNFQ{QTlizszN NVm1O2M5W0GQR1XS
SW1990 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3iZ2VKUUN3ME20MlA2QTB6IN88US=> MVfTRW5ITVJ?
LK-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID2e2pKSzVyPUSuNVEzQTNizszN Ml7UV2FPT0WU
ES5 NGjXPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvLWndKUUN3ME20MlE{QTh3IN88US=> NYL2VVhyW0GQR1XS
JVM-3 M{D0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz1TWM2OD12LkG4NlIzKM7:TR?= M3i1S3NCVkeHUh?=
RPMI-7951 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTRwMkK0NVMh|ryP MVjTRW5ITVJ?
Calu-6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTRwMke4PFEh|ryP MULTRW5ITVJ?
LC-2-ad MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nQeGlEPTB;ND6yPVU3QCEQvF2= M{PHbnNCVkeHUh?=
SW954 M3PzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHGT5RKSzVyPUSuNlk3PiEQvF2= MWXTRW5ITVJ?
H-EMC-SS MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTRwM{G4N|Eh|ryP NHPQcHZUSU6JRWK=
ES3 MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnNTWM2OD12LkO1OFQyKM7:TR?= NGXKO2lUSU6JRWK=
no-11 M1rBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEi3ZY1KSzVyPUSuN|U2PTRizszN NVfQN|ZKW0GQR1XS
LAN-6 MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXPfHM1UUN3ME20MlQ2OTh7IN88US=> NEmxOYNUSU6JRWK=
FTC-133 M4fDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTRwNUO5OUDPxE1? NXzLdmpVW0GQR1XS
8505C NInhfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rzNWlEPTB;ND61OFI{KM7:TR?= NYriSnNqW0GQR1XS
SW620 NF;p[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTRwNUewOVch|ryP M3rNdXNCVkeHUh?=
BCPAP NHj4dpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjTTWM2OD12Lk[zOFgyKM7:TR?= M1i0TnNCVkeHUh?=
SK-LU-1 M2G1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u1XWlEPTB;ND62OlA5QSEQvF2= MkHhV2FPT0WU
NCI-H1623 M1m4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfSZoNKSzVyPUSuO|AzOjhizszN Mnz6V2FPT0WU
C2BBe1 NH\mWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKyTWM2OD12Lke0NFA5KM7:TR?= NWPr[48xW0GQR1XS
GP5d MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPRV4hSUUN3ME20Mlc5Ozh6IN88US=> M13afnNCVkeHUh?=
NB6 MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInLb5JKSzVyPUSuPFYzODRizszN NUiwW|NoW0GQR1XS
MDA-MB-157 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHz[YFKSzVyPUSuPFg4PiEQvF2= MoHGV2FPT0WU
UMC-11 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonDTWM2OD12Lki4PVY1KM7:TR?= NWjycIFjW0GQR1XS
HCC1419 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq5NpVKSzVyPUSuPVAxPjNizszN Ml[yV2FPT0WU
NCI-H2029 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTiTWM2OD12Lkm0NVg2KM7:TR?= NF3BbIJUSU6JRWK=
LXF-289 NH7vXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3EfHlKSzVyPUWuNFM4OTlizszN NHPuU41USU6JRWK=
KINGS-1 M1rkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\tdWlEPTB;NT6wO|c1PCEQvF2= MV\TRW5ITVJ?
HD-MY-Z NFT4bIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HTWGlEPTB;NT6yN|k3QSEQvF2= MXvTRW5ITVJ?
ESS-1 M{jydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnBTWM2OD13LkK1OVk4KM7:TR?= NVvkNWtiW0GQR1XS
GI-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nsOWlEPTB;NT6yO|kzPiEQvF2= NHPIb3NUSU6JRWK=
RPMI-2650 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\qOoFKSzVyPUWuN|YyPiEQvF2= Mm\2V2FPT0WU
IA-LM MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XSeGlEPTB;NT6zPVg4OSEQvF2= M3nU[XNCVkeHUh?=
KP-4 MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTVwNE[zN|Qh|ryP NWezOpVzW0GQR1XS
G-402 NFnF[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\hTWM2OD13LkWxPFY2KM7:TR?= MULTRW5ITVJ?
OS-RC-2 M{jzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfTTWM2OD13LkWyOlA1KM7:TR?= M4TWfHNCVkeHUh?=
NCI-H1155 M{TUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDPSYtKSzVyPUWuOVQ6PTVizszN M4HVWHNCVkeHUh?=
OE19 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli0TWM2OD13Lk[4OlI1KM7:TR?= Ml;LV2FPT0WU
U-2-OS NEjzXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv6TWM2OD13Lki5NFE{KM7:TR?= MnPMV2FPT0WU
SCC-15 NWHVbnl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLtTWM2OD13LkmzOlYzKM7:TR?= MX7TRW5ITVJ?
NCI-H630 NF\PXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e4fGlEPTB;NT65PVQxPCEQvF2= MVLTRW5ITVJ?
PFSK-1 M3vQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf2TWRKSzVyPU[uNFUzPTlizszN MWPTRW5ITVJ?
NCI-H1770 NU\NZ29ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPHTWM2OD14LkKwPFc1KM7:TR?= M3Hzc3NCVkeHUh?=
SK-MEL-3 NFv2UlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\VfIFKSzVyPU[uOFI6OTVizszN M3jjZXNCVkeHUh?=
LB1047-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTZwNEe2NlUh|ryP NWHXW4ZlW0GQR1XS
NCI-H446 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTZwNkK5NlUh|ryP NY\YRZdNW0GQR1XS
SW780 MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP4eGROUUN3ME22MlcxOTh3IN88US=> M3fhR3NCVkeHUh?=
NEC8 M{jieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnnTWM2OD14Lke2OlMh|ryP NG\uOm1USU6JRWK=
NOMO-1 M{PjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTZwN{ixNVEh|ryP M1zKOXNCVkeHUh?=
COLO-668 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH1TWM2OD14Lki0N|g4KM7:TR?= NIPRXmVUSU6JRWK=
MC116 M4LGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O3O2lEPTB;Nj65N|g6PyEQvF2= MojBV2FPT0WU
HCC1937 M2jRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILVU3VKSzVyPU[uPVkzPTFizszN MWLTRW5ITVJ?
NCI-N87 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknJTWM2OD15LkG5Nlk{KM7:TR?= M2TWWnNCVkeHUh?=
COLO-320-HSR MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTdwMkK3N|gh|ryP M4m2d3NCVkeHUh?=
HCC1806 NHLzU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDFRYw5UUN3ME23MlI3ODR2IN88US=> NWjKO4d6W0GQR1XS
OVCAR-3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fmdmlEPTB;Nz6zN|A{QCEQvF2= MmPKV2FPT0WU
NUGC-3 M3XzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DhTGlEPTB;Nz6zPVY6PCEQvF2= MYnTRW5ITVJ?
SW1783 NVzZboI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTdwNEOxO|Uh|ryP NUX4fYpDW0GQR1XS
GCT NV7IdXJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXxTWM2OD15LkW2PVA3KM7:TR?= NUnXVmszW0GQR1XS
NCI-H2126 NWC1OY1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTdwN{O2NlUh|ryP MoPDV2FPT0WU
MEL-HO M3\jcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXxTWM2OD15Lke3NFU1KM7:TR?= NYf0OZRSW0GQR1XS
CAPAN-1 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfmXHp7UUN3ME23Mlc4OzV5IN88US=> NXWyRpJ7W0GQR1XS
SW756 NXjxcFNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K0dGlEPTB;Nz63PFM{OyEQvF2= NXLDeFRVW0GQR1XS
SKG-IIIa NV;te5duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTr[pFKSzVyPUeuPFE5QTJizszN NV3ZeVZtW0GQR1XS
HCE-T NUHEdnY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvvVXhRUUN3ME23Mlg4Pzh|IN88US=> MmfNV2FPT0WU
Ca-Ski M2S1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33GZmlEPTB;Nz65PVM5OyEQvF2= NVTvWVV2W0GQR1XS
COLO-684 Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRThwMEG4NVgh|ryP MXXTRW5ITVJ?
KYSE-70 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL1b4d1UUN3ME24MlA4PzJ7IN88US=> NWfP[Ho5W0GQR1XS
TI-73 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HSV2lEPTB;OD6yOVg2OSEQvF2= M{TSUXNCVkeHUh?=
BT-20 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fOZ2lEPTB;OD6yOlA2OiEQvF2= NYHPOW56W0GQR1XS
MHH-ES-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRThwNUG4N|Qh|ryP Ml\mV2FPT0WU
TE-12 M2DsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRThwNUm5N|Eh|ryP NIW1OGhUSU6JRWK=
YH-13 M3:3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon4TWM2OD16Lk[xNFA5KM7:TR?= MYrTRW5ITVJ?
SF126 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz5WWJKSzVyPUiuPFM5PjVizszN NInQfXhUSU6JRWK=
J82 NXPZSZNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHSPVd3UUN3ME24MlkxODN6IN88US=> NFn2c4tUSU6JRWK=
RCC10RGB NYDwVVVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRThwOUm1OlEh|ryP M4jTRXNCVkeHUh?=
SK-UT-1 NEXjUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrTcYdxUUN3ME25MlA1QTR3IN88US=> M3S0fnNCVkeHUh?=
LB2241-RCC NVHBeGdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTlwMUmxN|ch|ryP NVvBUldQW0GQR1XS
LB996-RCC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrRS4pKSzVyPUmuNVk5QSEQvF2= NEHocnlUSU6JRWK=
EPLC-272H MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7FTWM2OD17LkO3OlU4KM7:TR?= MVnTRW5ITVJ?
CTV-1 NYn1UXZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVOy[YhiUUN3ME25MlU3PTN{IN88US=> NUm3PWhWW0GQR1XS
HSC-2 NFrEeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\xfnpKSzVyPUmuOVc2PSEQvF2= MorZV2FPT0WU
SK-MEL-28 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTlwNkG4PVMh|ryP M2DYe3NCVkeHUh?=
MMAC-SF M1OyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ToRmlEPTB;OT62PFc2KM7:TR?= NVnqUJpJW0GQR1XS
CP50-MEL-B NFvrZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvG[mVtUUN3ME25Mlc2Pzh{IN88US=> M3nIRnNCVkeHUh?=
HT-1080 NWHJfJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDPXVRKSzVyPUmuO|c4OzlizszN MWPTRW5ITVJ?
HEC-1 M{\mW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nrb2lEPTB;MUCuN|M2OiEQvF2= NW\zc2hRW0GQR1XS
AGS MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFyLkO3OEDPxE1? NYrKdpo{W0GQR1XS
GAMG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTNWWRKSzVyPUGwMlUyPjJizszN M3myXnNCVkeHUh?=
SW48 M2GxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFyLkWxPFkh|ryP Mom2V2FPT0WU
U031 NU\mNYRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFyLkW5NFgh|ryP NFrjNYlUSU6JRWK=
OVCAR-5 MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDDSHFLUUN3ME2xNE43PDJ7IN88US=> MWXTRW5ITVJ?
SF295 M1L4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIexXodKSzVyPUGwMlY4ODRizszN MmLjV2FPT0WU
BHT-101 NHTvTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm5dZlKSzVyPUGwMlcyPzdizszN Mor1V2FPT0WU
VMRC-RCZ NWnxXnY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofhTWM2OD1zMT6zNlAyKM7:TR?= NWrZNW1lW0GQR1XS
ACHN NIrtN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmSwTWM2OD1zMT60NlEyKM7:TR?= M2\UUnNCVkeHUh?=
NCI-H526 MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT1TWM2OD1zMT61NFQ{KM7:TR?= MkPXV2FPT0WU
MN-60 Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFzLkWzPUDPxE1? MUnTRW5ITVJ?
NCI-H2291 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jEZmlEPTB;MUGuOVQ3PiEQvF2= MWLTRW5ITVJ?
SCC-25 NXm2UJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;zUopoUUN3ME2xNU44PTV4IN88US=> MUHTRW5ITVJ?
SK-MEL-2 M1z4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37JS2lEPTB;MUGuO|Y{PyEQvF2= MmHGV2FPT0WU
SN12C MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXaSHVKSzVyPUGxMlk{PTVizszN M1robXNCVkeHUh?=
NCI-H69 MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\CW21KSzVyPUGyMlQzOzRizszN NF3xO4lUSU6JRWK=
ME-180 NF35cYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXRWJFQUUN3ME2xNk44ODV2IN88US=> MX\TRW5ITVJ?
MC-IXC MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnPRYxKSzVyPUGyMlc2OThizszN Mmf6V2FPT0WU
NCI-H2347 NWnjNYdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;PeWlEPTB;MUKuO|YyPCEQvF2= MWXTRW5ITVJ?
M059J NXTF[Gk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\JVWlEPTB;MUKuO|czPyEQvF2= NXPobG9CW0GQR1XS
A2058 M1XDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3qdZBkUUN3ME2xNk45PjhzIN88US=> MULTRW5ITVJ?
VA-ES-BJ MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW4SnJKSzVyPUGyMlg4QDVizszN NI\lNpZUSU6JRWK=
Ca9-22 M3zvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3SfJlKSzVyPUGyMlk1PTFizszN MWrTRW5ITVJ?
KNS-42 NWrqfnl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\CTWM2OD1zMj65PVg1KM7:TR?= NYX1dodRW0GQR1XS
LoVo NFfZUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF|LkKzNVMh|ryP MX\TRW5ITVJ?
AM-38 NUDFbmZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF|LkK1OlYh|ryP Mo\XV2FPT0WU
NB5 NV\CZ3ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\1fGhKSzVyPUGzMlM4PTJizszN M1LHfXNCVkeHUh?=
L-363 M37mT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mki0TWM2OD1zMz60NFM{KM7:TR?= NYXFfHBGW0GQR1XS
SK-MEL-30 NFrwcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjUcZVKSzVyPUG0MlA3PDVizszN MonGV2FPT0WU
NCI-H1563 M3LETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnqdo1sUUN3ME2xOE43ODN7IN88US=> NFj4eIVUSU6JRWK=
NCI-H2228 MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF2Lk[wO|ch|ryP MULTRW5ITVJ?
MFM-223 M4O3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES3SXlKSzVyPUG1MlE5OTNizszN M1G0W3NCVkeHUh?=
LB831-BLC MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjse5Z[UUN3ME2xOU4zPzZ5IN88US=> MnvUV2FPT0WU
SW872 NFW0SmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nGcmlEPTB;MUWuN|A5PiEQvF2= NETvdFZUSU6JRWK=
NCI-H522 MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLFTWM2OD1zNT6zN|A3KM7:TR?= NUjsRod3W0GQR1XS
EW-1 NEjlWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e5RmlEPTB;MUWuOVQ3OiEQvF2= NXy3SVJTW0GQR1XS
HN MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\jXGlEPTB;MUWuOVk1OiEQvF2= MnrDV2FPT0WU
SW837 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInJfJNKSzVyPUG1Mlc5PDdizszN NEL5XWhUSU6JRWK=
SCC-9 NXK4[mY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF3LkixNVQh|ryP NFv6bYtUSU6JRWK=
MKN7 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;lTWM2OD1zNT65O|MzKM7:TR?= NYn6Wog3W0GQR1XS
KYSE-410 NWrN[lQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF4LkW5NUDPxE1? MojzV2FPT0WU
SK-N-DZ MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF4Lk[xNVYh|ryP MlTxV2FPT0WU
COR-L105 NEjUWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLMVmJKSzVyPUG2MlY2OjhizszN M{XFVHNCVkeHUh?=
LB2518-MEL Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH33NohKSzVyPUG2Mlg{QDlizszN NVfsc5FnW0GQR1XS
OVCAR-4 M4nvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnriTWM2OD1zNj64PFYzKM7:TR?= M1n5enNCVkeHUh?=
TK10 NXnnS|RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF4Lkm0O|Mh|ryP MlTOV2FPT0WU
KNS-62 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF4Lkm3O|ch|ryP MXrTRW5ITVJ?
RPMI-8866 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjPSHJ5UUN3ME2xO{4yPzN{IN88US=> NH:0eI9USU6JRWK=
HuP-T4 NGm3W5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDXT|hKSzVyPUG3MlI1QTVizszN MX7TRW5ITVJ?
CGTH-W-1 M3X1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrxTWM2OD1zNz61NlE6KM7:TR?= NGrZXYpUSU6JRWK=
T-24 NELVOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;6XWFSUUN3ME2xO{42OzR5IN88US=> M4OyPHNCVkeHUh?=
HT-3 NUL3SodHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D3S2lEPTB;MUeuOVkyPCEQvF2= NEfleWZUSU6JRWK=
KS-1 NXq5UphRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3q4cWlEPTB;MUeuOlc{KM7:TR?= M3zLSXNCVkeHUh?=
NCI-H1792 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljNTWM2OD1zNz63PVgh|ryP NFjObXRUSU6JRWK=
ABC-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX1eoVCUUN3ME2xO{45OTRzIN88US=> MXXTRW5ITVJ?
BPH-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nY[WlEPTB;MUiuNVY5PSEQvF2= MYDTRW5ITVJ?
A431 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\WR2lEPTB;MUiuOFEzPyEQvF2= NV71U5VtW0GQR1XS
T98G Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC5TWM2OD1zOD61NVU4KM7:TR?= M1zS[3NCVkeHUh?=
BHY MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XHPGlEPTB;MUiuPFY6KM7:TR?= NFXFO29USU6JRWK=
Capan-2 NWfsWWZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;ZdZFKSzVyPUG4MlkxPzhizszN MoLrV2FPT0WU
MDA-MB-175-VII MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfXTWM2OD1zOD65NlA6KM7:TR?= NXzWUoxLW0GQR1XS
CAL-27 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDQXZNKSzVyPUG5MlA1QDdizszN NGP3[IJUSU6JRWK=
AsPC-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF7Lki2OVch|ryP MmjEV2FPT0WU
KU812 NWDoUWlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTF7Lkm1O|Mh|ryP NFPK[GhUSU6JRWK=
NCI-H441 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3BTWM2OD1{MD6wNFEh|ryP MlWxV2FPT0WU
Mewo NF\UdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjpTWM2OD1{MD6xNlg5KM7:TR?= MYTTRW5ITVJ?
SK-MEL-24 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJyLkG0O|ch|ryP MWXTRW5ITVJ?
NCI-H727 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTYTWM2OD1{MD6yO|A1KM7:TR?= MkfrV2FPT0WU
EKVX M3fVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJyLk[wOkDPxE1? NYG3TpRyW0GQR1XS
RT-112 MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK1TWM2OD1{MD62NVIzKM7:TR?= NWnETFR{W0GQR1XS
CAMA-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJyLkm4NFMh|ryP MofqV2FPT0WU
SW900 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJzLkCxOFkh|ryP NHWw[XVUSU6JRWK=
NCI-H23 NXnlW41FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJzLkGyO|ch|ryP NW\EVHNWW0GQR1XS
SK-PN-DW NIrnN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJzLkG2OFkh|ryP MUXTRW5ITVJ?
BB30-HNC NYn3[4tuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPkN4FlUUN3ME2yNU4zPzR3IN88US=> NVPuTWF4W0GQR1XS
VM-CUB-1 M1;RdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXMe4hKSzVyPUKxMlM2OzZizszN M4LlPHNCVkeHUh?=
IST-MEL1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJzLkO2PVIh|ryP NFzzcG9USU6JRWK=
CTB-1 Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHiR4tCUUN3ME2yNU41PzV3IN88US=> MXLTRW5ITVJ?
LCLC-103H M3POcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT4dG1KSzVyPUKyMlE2QDJizszN MmryV2FPT0WU
PANC-03-27 Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7YZ5FKSzVyPUKyMlUyPjlizszN NYPpO4VEW0GQR1XS
HTC-C3 NEXVT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DOdWlEPTB;MkKuOVU2PSEQvF2= M4W2VHNCVkeHUh?=
TE-8 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i0[2lEPTB;MkOuNlU3PSEQvF2= M4C1cnNCVkeHUh?=
NCI-H292 NVLiOmZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLxTWM2OD1{NT6zOVM3KM7:TR?= MYfTRW5ITVJ?
COLO-680N M3zCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ3Lk[zNlkh|ryP MnzEV2FPT0WU
KYSE-520 NWX3O3J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjMTWM2OD1{NT62OFQh|ryP M3jFeHNCVkeHUh?=
NB10 NEXHOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS2NmdWUUN3ME2yOk4{OTF5IN88US=> NInSeFJUSU6JRWK=
NCI-H661 M4nveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ4LkS3NVMh|ryP MWrTRW5ITVJ?
GMS-10 M1mxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvkTWM2OD1{Nj64OlM5KM7:TR?= NWT6O|hNW0GQR1XS
NCI-H2122 NHi1So1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrqZVNOUUN3ME2yOk46QTl6IN88US=> MXrTRW5ITVJ?
OVCAR-8 MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXhcooxUUN3ME2yO{4xPjN6IN88US=> NYLqZ2FDW0GQR1XS
DJM-1 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[1bGlEPTB;MkeuNVQ2PCEQvF2= NHK5PWdUSU6JRWK=
UACC-893 MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ5Lkm4O|gh|ryP NGLNcGFUSU6JRWK=
C8166 NEPhS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTBTWM2OD1{OD62PVM5KM7:TR?= NGfPRnRUSU6JRWK=
NCI-H1693 NF3MVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L0PGlEPTB;MkiuOlk4PSEQvF2= NX7senR2W0GQR1XS
TYK-nu NX35fXc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzHTWM2OD1|MD6wN|Q2KM7:TR?= M2\L[3NCVkeHUh?=
SW1710 M1nsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTNyLkGyOkDPxE1? NWPRS5VJW0GQR1XS
A375 MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjOfJNKSzVyPUOwMlMzPDNizszN NYDxe3oyW0GQR1XS
HMV-II MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrPWm4yUUN3ME2zNU4{PTl{IN88US=> NW\3VY1CW0GQR1XS
NCI-H2087 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTNzLk[zOVIh|ryP M{PPfHNCVkeHUh?=
CAL-54 NXTye3NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjHSYJWUUN3ME2zNU44OjRzIN88US=> Ml7WV2FPT0WU
HCC70 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHMTWM2OD1|Mj6xN|g4KM7:TR?= M1PIWnNCVkeHUh?=
ES1 M1zQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv5TWM2OD1|Mj6zNFYzKM7:TR?= MWPTRW5ITVJ?
NCI-H1355 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTN|LkKwOEDPxE1? M{K1SnNCVkeHUh?=
CFPAC-1 NV7EZmhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PPd2lEPTB;M{OuNlM{OiEQvF2= NI\KV2VUSU6JRWK=
MKN28 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPzTWM2OD1|Mz6zPFA6KM7:TR?= NYPx[XF4W0GQR1XS
HDLM-2 NHzPZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm0ZWJsUUN3ME2zN{43QTNzIN88US=> NX:0Z2tJW0GQR1XS
PANC-10-05 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\EbFNKSzVyPUO0MlExOTRizszN MkDkV2FPT0WU
SAS NVrZRoF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nvb2lEPTB;M{SuOFU3PSEQvF2= NF\pc3lUSU6JRWK=
HCC1395 M2LpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTN2LkexPFYh|ryP M2rES3NCVkeHUh?=
8305C MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXKTWM2OD1|NT64OFE2KM7:TR?= Mlv6V2FPT0WU
KM12 NHqw[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTN4Lke1OFch|ryP NITNSlZUSU6JRWK=
SW1116 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M375TmlEPTB;M{euOVk6OiEQvF2= M3njXXNCVkeHUh?=
SK-MEL-1 NEjacWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3KxNWlEPTB;M{iuN|M5QSEQvF2= M1K5Z3NCVkeHUh?=
HCC2218 MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{K4WGlEPTB;M{iuOlUyQSEQvF2= MlzyV2FPT0WU
T84 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTN6Lke0NFkh|ryP MULTRW5ITVJ?
ETK-1 M1HFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn5WFFKSzVyPUO5MlAzOiEQvF2= NHryXGFUSU6JRWK=
COLO-800 NH3TXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy5fHBWUUN3ME2zPU4{QDZ6IN88US=> NVXS[llMW0GQR1XS
CAL-12T NUfmV4ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTN7LkWyPFEh|ryP MkSwV2FPT0WU
ACN NF7PSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULySVR[UUN3ME20NE41QTFzIN88US=> MV7TRW5ITVJ?
SJSA-1 NWTpeIRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHqXXNKSzVyPUSxMlE2QTZizszN MXvTRW5ITVJ?
PSN1 MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvaTodMUUN3ME20NU4yPzR7IN88US=> MnHFV2FPT0WU
D-566MG M2HzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HUXmlEPTB;NEGuNlA5PiEQvF2= M1Lo[3NCVkeHUh?=
EGI-1 NUHUXXJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTR{LkSyPEDPxE1? MVnTRW5ITVJ?
A204 NH;kdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnryTWM2OD12Mj62N|g5KM7:TR?= NV;Re3p2W0GQR1XS
Saos-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\QcJlTUUN3ME20Nk45OzZ7IN88US=> MVjTRW5ITVJ?
SNU-C2B NIHIOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTR|Lk[4O|gh|ryP Mk\EV2FPT0WU
HLE M33pdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;YRnpEUUN3ME20OE4xQDV4IN88US=> MYjTRW5ITVJ?
SW1463 NFLKUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvaSmtKSzVyPUS0Mlk6PzFizszN M4f5bHNCVkeHUh?=
DSH1 NFjpWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofnTWM2OD12NT6wNFM{KM7:TR?= MnrUV2FPT0WU
MCF7 M1XiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vzSWlEPTB;NEWuOVA2OSEQvF2= MXrTRW5ITVJ?
K5 M2Hpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDyUlhtUUN3ME20OU46PDB3IN88US=> NX22S5pHW0GQR1XS
NCI-H358 MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTR5LkKxOUDPxE1? NHTKdlBUSU6JRWK=
NCI-H2030 NF3FToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTR5LkKzO|Qh|ryP MVjTRW5ITVJ?
SW948 MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlThTWM2OD12Nz60OlQh|ryP M1rSVnNCVkeHUh?=
BALL-1 M3PqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LYPGlEPTB;NEeuOlE3QCEQvF2= M4OwUXNCVkeHUh?=
TE-9 NFq0VIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\6TWM2OD12Nz65OVgyKM7:TR?= M1K5eHNCVkeHUh?=
SK-N-FI NXrsVWU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTR6LkCzOVgh|ryP MULTRW5ITVJ?
KALS-1 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHOxbYZKSzVyPUS4MlEzQDlizszN M3rGN3NCVkeHUh?=
HO-1-N-1 NFr3bpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTrPW9kUUN3ME20PE44PDR3IN88US=> NFjne21USU6JRWK=
NCI-H2452 NV24bHJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTR7LkGxOVIh|ryP NVe0V4VQW0GQR1XS
OC-314 NETiNndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4S3VmlEPTB;NEmuOlg{PCEQvF2= M4Dnd3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+corn oil
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Related Antibodies

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID